Shorla Pharma

Shorla Oncology develops and commercializes oncology drugs for indications where existing treatments are limited, in shortage, or inadequate. The company's portfolio includes products such as TEPYLUTE, IMKELDI, JYLAMVO, and Nelarabine Injection, targeting conditions like T-cell acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. They focus on providing accessible and affordable niche cancer treatments to patients through a pipeline of specialty pharmaceutical products.